Cargando…
Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis
OBJECTIVES: Most therapies for autoimmune and inflammatory diseases either neutralize or suppress production of inflammatory cytokines produced by activated macrophages (e.g., TNFα, IL-1, IL-6, IL-17, GM-CSF). However, no approved therapies directly target this activated subset of macrophages. METHO...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555977/ https://www.ncbi.nlm.nih.gov/pubmed/31174578 http://dx.doi.org/10.1186/s13075-019-1912-0 |
_version_ | 1783425249110392832 |
---|---|
author | Hu, Yingwen Wang, Bingbing Shen, Jiayin Low, Stewart A. Putt, Karson S. Niessen, Hans W. M. Matteson, Eric L. Murphy, Linda Ruppert, Clemens Jansen, Gerrit Oliver, Stephen J. Feng, Yang Dimitrov, Dimiter S. Nickerson-Nutter, Cheryl Low, Philip S. |
author_facet | Hu, Yingwen Wang, Bingbing Shen, Jiayin Low, Stewart A. Putt, Karson S. Niessen, Hans W. M. Matteson, Eric L. Murphy, Linda Ruppert, Clemens Jansen, Gerrit Oliver, Stephen J. Feng, Yang Dimitrov, Dimiter S. Nickerson-Nutter, Cheryl Low, Philip S. |
author_sort | Hu, Yingwen |
collection | PubMed |
description | OBJECTIVES: Most therapies for autoimmune and inflammatory diseases either neutralize or suppress production of inflammatory cytokines produced by activated macrophages (e.g., TNFα, IL-1, IL-6, IL-17, GM-CSF). However, no approved therapies directly target this activated subset of macrophages. METHODS: First, we undertook to examine whether the folate receptor beta (FR-β) positive subpopulation of macrophages, which marks the inflammatory subset in animal models of rheumatoid arthritis, might constitute the prominent population of macrophages in inflamed lesions in humans. Next, we utilized anti-FR-β monoclonal antibodies capable of mediating antibody-dependent cell cytotoxicity (ADCC) to treat animal models of rheumatoid arthritis and peritonitis. RESULTS: Human tissue samples of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, chronic obstructive pulmonary disease, systemic lupus erythematosus, psoriasis, and scleroderma are all characterized by dramatic accumulation of macrophages that express FR-β, a protein not expressed on resting macrophages or any other healthy tissues. A monoclonal antibody to FR-β accumulates specifically in inflamed lesions of murine inflammatory disease models and successfully treats such models of rheumatoid arthritis and peritonitis. More importantly, elimination of FR-β-positive macrophages upon treatment with an anti-FR-β monoclonal antibody promotes the departure of other immune cells, including T cells, B cells, neutrophils, and dendritic cells from the inflamed lesions. CONCLUSIONS: These data suggest that specific elimination of FR-β-expressing macrophages may constitute a highly specific therapy for multiple autoimmune and inflammatory diseases and that a recently developed human anti-human FR-β monoclonal antibody (m909) might contribute to suppression of this subpopulation of macrophages. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13075-019-1912-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6555977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65559772019-06-10 Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis Hu, Yingwen Wang, Bingbing Shen, Jiayin Low, Stewart A. Putt, Karson S. Niessen, Hans W. M. Matteson, Eric L. Murphy, Linda Ruppert, Clemens Jansen, Gerrit Oliver, Stephen J. Feng, Yang Dimitrov, Dimiter S. Nickerson-Nutter, Cheryl Low, Philip S. Arthritis Res Ther Research Article OBJECTIVES: Most therapies for autoimmune and inflammatory diseases either neutralize or suppress production of inflammatory cytokines produced by activated macrophages (e.g., TNFα, IL-1, IL-6, IL-17, GM-CSF). However, no approved therapies directly target this activated subset of macrophages. METHODS: First, we undertook to examine whether the folate receptor beta (FR-β) positive subpopulation of macrophages, which marks the inflammatory subset in animal models of rheumatoid arthritis, might constitute the prominent population of macrophages in inflamed lesions in humans. Next, we utilized anti-FR-β monoclonal antibodies capable of mediating antibody-dependent cell cytotoxicity (ADCC) to treat animal models of rheumatoid arthritis and peritonitis. RESULTS: Human tissue samples of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, chronic obstructive pulmonary disease, systemic lupus erythematosus, psoriasis, and scleroderma are all characterized by dramatic accumulation of macrophages that express FR-β, a protein not expressed on resting macrophages or any other healthy tissues. A monoclonal antibody to FR-β accumulates specifically in inflamed lesions of murine inflammatory disease models and successfully treats such models of rheumatoid arthritis and peritonitis. More importantly, elimination of FR-β-positive macrophages upon treatment with an anti-FR-β monoclonal antibody promotes the departure of other immune cells, including T cells, B cells, neutrophils, and dendritic cells from the inflamed lesions. CONCLUSIONS: These data suggest that specific elimination of FR-β-expressing macrophages may constitute a highly specific therapy for multiple autoimmune and inflammatory diseases and that a recently developed human anti-human FR-β monoclonal antibody (m909) might contribute to suppression of this subpopulation of macrophages. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13075-019-1912-0) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-07 2019 /pmc/articles/PMC6555977/ /pubmed/31174578 http://dx.doi.org/10.1186/s13075-019-1912-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Hu, Yingwen Wang, Bingbing Shen, Jiayin Low, Stewart A. Putt, Karson S. Niessen, Hans W. M. Matteson, Eric L. Murphy, Linda Ruppert, Clemens Jansen, Gerrit Oliver, Stephen J. Feng, Yang Dimitrov, Dimiter S. Nickerson-Nutter, Cheryl Low, Philip S. Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis |
title | Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis |
title_full | Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis |
title_fullStr | Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis |
title_full_unstemmed | Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis |
title_short | Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis |
title_sort | depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555977/ https://www.ncbi.nlm.nih.gov/pubmed/31174578 http://dx.doi.org/10.1186/s13075-019-1912-0 |
work_keys_str_mv | AT huyingwen depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT wangbingbing depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT shenjiayin depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT lowstewarta depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT puttkarsons depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT niessenhanswm depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT mattesonericl depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT murphylinda depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT ruppertclemens depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT jansengerrit depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT oliverstephenj depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT fengyang depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT dimitrovdimiters depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT nickersonnuttercheryl depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis AT lowphilips depletionofactivatedmacrophageswithafolatereceptorbetaspecificantibodyimprovessymptomsinmousemodelsofrheumatoidarthritis |